[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 31 of about 31
3. Yamauchi K, Yasuda M: Comparison in treatments of nonleukemic granulocytic sarcoma: report of two cases and a review of 72 cases in the literature. Cancer; 2002 Mar 15;94(6):1739-46
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison in treatments of nonleukemic granulocytic sarcoma: report of two cases and a review of 72 cases in the literature.
  • BACKGROUND: The purpose of this study was to reveal the clinical characteristics of nonleukemic granulocytic sarcoma (GS) and an association between the therapeutic regimens and the nonleukemic period.
  • These patients were divided into 3 groups by therapeutic regimens; Group I included 12 patients who received only biopsy or surgical resection of the tumor, Group II was 20 patients who received local irradiation for the tumor, and Group III consisted of 42 patients who received systemic chemotherapy.
  • In Group III, the period in the patients who were treated with chemotherapy given to ANLL was compared with that in the patients who received chemotherapy used for malignant lymphoproliferative disorders (MLPDs).
  • Preferential sites of GS were the small intestine, mediastinum, epidural site, uterus, and ovary, which often are difficult for the detection and diagnosis in addition to the skin and lymph nodes known commonly.
  • The nonleukemic period after the diagnosis of GS was significantly longer in Group III than in the other groups (median, 12 months in Group III vs. 3 and 6 months in Groups I and II, respectively).
  • The aggressive chemotherapy given to ANLL led to a longer nonleukemic period than the chemotherapy used for MLPDs.
  • CONCLUSIONS: To reduce the risk of subsequent ANLL in patients with nonleukemic GS, it is important that accurate histologic diagnosis is established initially for GS and that all isolated cases of GS, even those that appear to be cured by resection or irradiation of the tumor, are treated with intensive chemotherapy similar to that used to treat ANLL during the nonleukemic period as soon as possible.
  • [MeSH-major] Leukemia, Myeloid, Acute / etiology. Sarcoma, Myeloid / pathology. Soft Tissue Neoplasms / pathology
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Diagnosis, Differential. Humans. Lymphoma / diagnosis. Male. Middle Aged. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002 American Cancer Society.
  • (PMID = 11920536.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Comparative Study; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 59
  •  go-up   go-down


Advertisement
4. Koizumi K, Haraguchi S, Mikami I, Kubokura H, Okada D, Yamagishi S, Kinoshita H, Enomoto Y, Shimizu K, Maeda M: Video-assisted thoracic surgery for Ewing's sarcoma of the mediastinum in a 3-year-old girl. Ann Thorac Cardiovasc Surg; 2005 Apr;11(2):117-20
Genetic Alliance. consumer health - Ewing's Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Video-assisted thoracic surgery for Ewing's sarcoma of the mediastinum in a 3-year-old girl.
  • We report of the experience of video-assisted thoracic surgery (VATS) for a Ewing's sarcoma at the posterior mediastinum in a 3 year old girl.
  • The patient developed common cold like symptoms and developed rapid lower limb paraplegia.
  • A chest computed tomography (CT) showed a solid mass adjacent to the vertebrae.
  • This was diagnosed as a Ewing's sarcoma histopathologically by CT-guided needle biopsy (CT-NB).
  • As the tumor reduced after induction chemotherapy, with improvement of paraplegia, the patient underwent thoracoscopic examination followed by complete removal of the tumor by VATS.
  • VATS could be an option as combined therapy for Ewing's sarcoma when well controlled and localized under induction therapy.
  • [MeSH-major] Mediastinal Neoplasms / surgery. Sarcoma, Ewing / surgery. Thoracic Surgery, Video-Assisted
  • [MeSH-minor] Child, Preschool. Combined Modality Therapy. Female. Humans. Magnetic Resonance Imaging. Spinal Cord Compression / etiology. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15900244.001).
  • [ISSN] 1341-1098
  • [Journal-full-title] Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia
  • [ISO-abbreviation] Ann Thorac Cardiovasc Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


7. Tanaka H, Sasayama T, Nishihara M, Arai A, Kawamura A, Kanomata N, Itoh T, Kohmura E: Brain metastasis of undifferentiated sarcoma and response to temozolomide treatment. Case report. Neurol Med Chir (Tokyo); 2010;50(8):689-93
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Brain metastasis of undifferentiated sarcoma and response to temozolomide treatment. Case report.
  • A 33-year-old woman presented with rare brain metastases from undifferentiated high-grade sarcoma manifesting as headache and vomiting.
  • Magnetic resonance (MR) imaging demonstrated multiple tumors in the brain, subcutaneous soft tissue, and mediastinum.
  • The patient underwent surgery, followed by chemotherapy and radiotherapy.
  • The histological diagnosis was undifferentiated high-grade sarcoma.
  • The patient underwent high-dose methotrexate therapy, but showed no response.
  • Promoter hypermethylation in the O(6)-methylguanine-deoxyribonucleic acid methyltransferase (MGMT) genes was detected and MGMT protein expression was negative in the recurrent tumor, so temozolomide (TMZ) salvage chemotherapy was given, and follow-up MR imaging showed tumor reduction.
  • This case suggests that TMZ may be effective for brain metastasis of undifferentiated sarcoma without MGMT protein expression.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Brain Neoplasms / therapy. Dacarbazine / analogs & derivatives. Neoplasm Recurrence, Local / therapy. Sarcoma / therapy
  • [MeSH-minor] Adult. Combined Modality Therapy. DNA Modification Methylases / genetics. DNA Modification Methylases / metabolism. DNA Repair Enzymes / genetics. DNA Repair Enzymes / metabolism. Female. Gene Silencing. Humans. Salvage Therapy. Soft Tissue Neoplasms / enzymology. Soft Tissue Neoplasms / genetics. Soft Tissue Neoplasms / pathology. Soft Tissue Neoplasms / therapy. Tumor Suppressor Proteins / genetics. Tumor Suppressor Proteins / metabolism

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20805657.001).
  • [ISSN] 1349-8029
  • [Journal-full-title] Neurologia medico-chirurgica
  • [ISO-abbreviation] Neurol. Med. Chir. (Tokyo)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Tumor Suppressor Proteins; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; EC 2.1.1.- / DNA Modification Methylases; EC 2.1.1.63 / MGMT protein, human; EC 6.5.1.- / DNA Repair Enzymes
  •  go-up   go-down


8. Hsieh PP, Ho WL, Peng HC, Lee T: Synovial sarcoma of the mediastinum. Zhonghua Yi Xue Za Zhi (Taipei); 2002 Feb;65(2):83-5
Genetic Alliance. consumer health - Synovial sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synovial sarcoma of the mediastinum.
  • Synovial sarcomas are exceedingly rare neoplasms of the mediastinum.
  • We herein report a case of synovial sarcoma occurring in the mediastinum of an 11-year-old boy.
  • The patient presented with superior vena cava syndrome, and the tumor was found located in the upper superior mediastinum.
  • The biopsy showed the typical biphasic pattern of synovial sarcoma.
  • After surgery, the patient received radiotherapy and chemotherapy, and was still alive 2 years after diagnosis.
  • [MeSH-major] Mediastinal Neoplasms / pathology. Sarcoma, Synovial / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12014364.001).
  • [ISSN] 0578-1337
  • [Journal-full-title] Zhonghua yi xue za zhi = Chinese medical journal; Free China ed
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi (Taipei)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China (Republic : 1949- )
  •  go-up   go-down


9. Katakura H, Fukuse T, Shiraishi I, Hayatsu E, Nishijo K, Toguchida J, Nakashima Y, Wada H: Mediastinal synovial sarcoma. Thorac Cardiovasc Surg; 2009 Apr;57(3):183-5
Genetic Alliance. consumer health - Synovial sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mediastinal synovial sarcoma.
  • Synovial sarcoma of the mediastinum is a rare neoplasm that has overlapping histological and immunophenotypic features with other tumors in the differential diagnosis.
  • The doubling time of the main tumor was 11.8 days.
  • Reverse transcription-PCR confirmed the diagnosis of synovial sarcoma.
  • The patient rejected chemotherapy or radiation therapy, and had recurrent tumors only one month after the operation.
  • [MeSH-major] Mediastinal Neoplasms / pathology. Sarcoma, Synovial / pathology
  • [MeSH-minor] Aged. Fatal Outcome. Female. Gene Expression Regulation, Neoplastic. Humans. Neoplasm Invasiveness. Neoplasm Recurrence, Local. Oncogene Proteins, Fusion / genetics. Palliative Care. Positron-Emission Tomography. Thoracotomy. Tomography, X-Ray Computed. Treatment Refusal

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19330763.001).
  • [ISSN] 0171-6425
  • [Journal-full-title] The Thoracic and cardiovascular surgeon
  • [ISO-abbreviation] Thorac Cardiovasc Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Oncogene Proteins, Fusion; 0 / SYT-SSX fusion protein
  •  go-up   go-down


10. Gotoh M, Furukawa S, Motoishi M, Fujimoto T, Okazaki T, Matsukura T, Hanawa T, Yamashita N, Matsui T, Kuwabara M, Matsubara Y: Synovial sarcoma of the mediastinum: report of a case. Surg Today; 2004;34(6):521-4
Genetic Alliance. consumer health - Synovial sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synovial sarcoma of the mediastinum: report of a case.
  • We report a case of synovial sarcoma of the mediastinum, a very rare tumor, in a 50-year-old man hospitalized with anterior chest pain.
  • Chest X-ray and computed tomography (CT) on admission showed a 10 x 8-cm mass in the right anterior mediastinal space, compressing the superior vena cava.
  • A diagnosis of sarcoma was established by a CT-guided percutaneous needle biopsy.
  • Systemic examination revealed no metastasis to the contralateral pleural cavity or other distant organs, and we resected the mediastinal sarcoma.
  • Pathological and immunohistochemical analyses confirmed a diagnosis of monophasic synovial sarcoma.
  • The patient is alive with recurrence 9 months after his operation, and is receiving chemotherapy with ifosfamide.
  • [MeSH-major] Mediastinal Neoplasms / pathology. Mediastinal Neoplasms / surgery. Sarcoma, Synovial / pathology. Sarcoma, Synovial / surgery
  • [MeSH-minor] Humans. Immunohistochemistry. Male. Middle Aged. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15170549.001).
  • [ISSN] 0941-1291
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


11. Tirabosco R, Lang-Lazdunski L, Diss TC, Amary MF, Rodriguez-Justo M, Landau D, Lorenzi W, Flanagan AM: Clear cell sarcoma of the mediastinum. Ann Diagn Pathol; 2009 Jun;13(3):197-200
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clear cell sarcoma of the mediastinum.
  • A 59-year-old woman presented with a large mediastinal mass.
  • The diagnosis of clear cell sarcoma was supported by demonstrating the presence of an EWS gene rearrangement by fluorescence in situ hybridization.
  • To the best of our knowledge, primary mediastinal clear cell sarcoma has not been previously reported in the literature.
  • We present the case and discuss the differential diagnosis.
  • [MeSH-major] Mediastinal Neoplasms / genetics. Mediastinal Neoplasms / pathology. RNA-Binding Protein EWS / genetics. Sarcoma, Clear Cell / genetics. Sarcoma, Clear Cell / secondary
  • [MeSH-minor] Adenocarcinoma / pathology. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / analysis. Bone Neoplasms / drug therapy. Bone Neoplasms / secondary. Diagnosis, Differential. Female. Gastrointestinal Stromal Tumors / pathology. Gene Rearrangement. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Lymphatic Metastasis / pathology. Middle Aged. Reverse Transcriptase Polymerase Chain Reaction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19433300.001).
  • [ISSN] 1532-8198
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA-Binding Protein EWS
  •  go-up   go-down


12. Nakagawa Y, Shimizu T, Terakado M, Hiranuma H, Matsumoto K, Takahashi N, Hashimoto S: [A case of synovial sarcoma of the mediastinum]. Nihon Kokyuki Gakkai Zasshi; 2010 Oct;48(10):734-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of synovial sarcoma of the mediastinum].
  • A 65-year-old man consulted our hospital with a complaint of bloody sputum in February 2006, and chest computed tomography (CT) showed a mediastinal tumor.
  • Thus, we confirmed a diagnosis of synovial sarcoma.
  • The patient received chemotherapy, radiation therapy and hyperthermia therapy, but the tumor progressed and he died in October 2007.
  • Synovial sarcoma commonly occurs in the vicinity of the large joints.
  • We report an important case of mediastinal synovial sarcoma, which is comparatively rare.
  • [MeSH-major] Mediastinal Neoplasms / pathology. Sarcoma, Synovial / pathology

  • Genetic Alliance. consumer health - Synovial sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21066860.001).
  • [ISSN] 1343-3490
  • [Journal-full-title] Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society
  • [ISO-abbreviation] Nihon Kokyuki Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


13. Mirzoyan M, Muslimani A, Setrakian S, Swedeh M, Daw HA: Primary pleuropulmonary synovial sarcoma. Clin Lung Cancer; 2008 Sep;9(5):257-61
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary pleuropulmonary synovial sarcoma.
  • Pleuropulmonary synovial sarcoma (PPSS) is increasingly recognized as a subtype of sarcoma because of the recent identification of a distinctive chromosomal translocation specific to synovial sarcoma.
  • Soft-tissue synovial sarcoma is far more common than PPSS and typically develops in para-articular locations of the extremities, affects young and middle-aged adults, with no difference in distribution between the sexes, and has well-documented radiologic manifestations.
  • Pleuropulmonary synovial sarcoma can arise in the chest wall, heart, mediastinum, pleura, or lung, and it shares patient demographics and several imaging features with its soft-tissue counterpart.
  • Magnetic resonance imaging provides superior demonstration of nodular soft tissue and multilocular fluid-filled internal components of PPSS, in addition to peripheral rim enhancement after the intravenous administration of a gadoliniumbased contrast material such as gadopentetate dimeglumine.
  • Current treatment consists of surgical resection followed by chemotherapy, radiation therapy, or both.
  • [MeSH-major] Lung Neoplasms / pathology. Pleural Neoplasms / pathology. Sarcoma, Synovial / pathology

  • Genetic Alliance. consumer health - Synovial sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18824448.001).
  • [ISSN] 1525-7304
  • [Journal-full-title] Clinical lung cancer
  • [ISO-abbreviation] Clin Lung Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 51
  •  go-up   go-down


14. Frazier AA, Franks TJ, Pugatch RD, Galvin JR: From the archives of the AFIP: Pleuropulmonary synovial sarcoma. Radiographics; 2006 May-Jun;26(3):923-40
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] From the archives of the AFIP: Pleuropulmonary synovial sarcoma.
  • Pleuropulmonary synovial sarcoma (PPSS) is increasingly recognized as a subtype of sarcoma because of the recent identification of a distinctive chromosomal translocation specific to synovial sarcoma.
  • Soft-tissue synovial sarcoma is far more common than PPSS and typically develops in para-articular locations of the extremities; affects young and middle-aged adults, with no difference in distribution between the sexes; and has well-documented radiologic manifestations.
  • PPSS may arise in the chest wall, heart, mediastinum, pleura, or lung, and it shares patient demographics and several imaging features with its soft-tissue counterpart.
  • Magnetic resonance imaging provides superior demonstration of nodular soft tissue and multilocular fluid-filled internal components of PPSS, in addition to peripheral rim enhancement after the intravenous administration of a gadolinium-based contrast material such as gadopentetate dimeglumine.
  • Current treatment consists of surgical resection followed by chemotherapy, radiation therapy, or both.
  • [MeSH-major] Image Enhancement / methods. Lung Neoplasms / diagnosis. Magnetic Resonance Imaging / methods. Pleural Neoplasms / diagnosis. Sarcoma, Synovial / diagnosis

  • Genetic Alliance. consumer health - Synovial sarcoma.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16702463.001).
  • [ISSN] 1527-1323
  • [Journal-full-title] Radiographics : a review publication of the Radiological Society of North America, Inc
  • [ISO-abbreviation] Radiographics
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media
  • [Number-of-references] 47
  •  go-up   go-down


15. Vuky J, Bains M, Bacik J, Higgins G, Bajorin DF, Mazumdar M, Bosl GJ, Motzer RJ: Role of postchemotherapy adjunctive surgery in the management of patients with nonseminoma arising from the mediastinum. J Clin Oncol; 2001 Feb 01;19(3):682-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of postchemotherapy adjunctive surgery in the management of patients with nonseminoma arising from the mediastinum.
  • PURPOSE: To evaluate the role of postchemotherapy surgery in patients with nonseminomatous germ cell tumors arising from the anterior mediastinum.
  • PATIENTS AND METHODS: Thirty-two patients with nonseminoma arising from a mediastinal primary site were treated on a clinical trial at our center, and they underwent postchemotherapy surgery.
  • Viable tumor included embryonal carcinoma, choriocarcinoma, yolk sac carcinoma, seminoma, and teratoma with malignant transformation to nongerm cell histology (eg, sarcoma).
  • CONCLUSION: Surgical resection of residual mass after chemotherapy plays an integral role in the management of patients with primary mediastinal nonseminoma.
  • Teratoma and viable tumor were found in the majority of resected residua after chemotherapy.
  • Because patients who undergo conventional salvage chemotherapy programs rarely achieve long-term disease-free status, selected patients with elevated markers after chemotherapy are considered candidates for surgical resection.
  • [MeSH-major] Germinoma / surgery. Mediastinal Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / blood. Chorionic Gonadotropin, beta Subunit, Human / blood. Humans. Lung Neoplasms / secondary. Male. Middle Aged. Neoadjuvant Therapy. Prognosis. Prospective Studies. Randomized Controlled Trials as Topic. Survival Rate. alpha-Fetoproteins / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11157018.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA-09207-23
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Chorionic Gonadotropin, beta Subunit, Human; 0 / alpha-Fetoproteins
  •  go-up   go-down


16. Comandone A, Boglione A, Pochettino P, Berno E, Inguì M, Papotti M, Borasio P, Maggi G, Brach Del Prever E, Gino G: Primary sarcomas of the lungs and mediastinum: Clinicopathological study and therapy results of Piedmontese Group for Sarcomas. J Clin Oncol; 2009 May 20;27(15_suppl):e21509

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary sarcomas of the lungs and mediastinum: Clinicopathological study and therapy results of Piedmontese Group for Sarcomas.
  • : e21509 Background: Primary sarcomas of the lungs and mediastinum are rare and few data are reported on treatment and results of therapy.
  • Pts characteristics: median age 41 (19-80 y), male/female 19/12; symptoms at diagnosis: dyspnoea (42%), chest and shoulder pain (39%), cough (35%), hemophtoae (13%), discomfort (10%).
  • 4 pts had a previous history of mediastinal radiation for Hodgkin's and non-Hodgkin's linfomas.
  • 5 mediastinal tumours were located as follows: 2 in anterior part, 1 in posterior and 2 in the middle (sarcomas of the heart).
  • RESULTS: In 20/31 cases the tumour was immediately resected (3 mediastinal masses and 17 lung sarcomas).
  • Neoadjuvant chemotherapy was performed in 4 cases (3 resected).
  • The histology were: peripheral nerve tumour 7, leiomyosarcoma 4, MFH 2, fibrosarcoma 2, liposarcoma 1, angiosarcoma 2, undifferentiated sarcoma 1, solitary fibrous tumour 2, rhabdomyosarcoma 2, synovialsarcoma 2, pulmonary artery sarcoma 1, pleuropolmonary blastoma 1, malignant hemangiopericytoma 1, mixoid chondrosarcoma 1, ectopic osteosarcoma 1, aggressive fibromatosis 1.
  • Only 4 pts received neoadjuvant chemotherapy, 11 adjuvant CT, 5 exclusive CT + RT for inoperable disease.
  • CONCLUSIONS: Primary sarcomas of the lungs and mediastinum have a very severe prognosis.
  • Surgical resection is the fundamental therapy, but in the future the role of neoadjuvant CT will increase.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963441.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Indelicato DJ, Keole SR, Shahlaee AH, Morris CG, Gibbs CP, Scarborough MT, Islam S, Marcus RB: Ewing tumors of the chest wall: Local control and long-term outcomes. J Clin Oncol; 2009 May 20;27(15_suppl):e21501

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : e21501 Background: Primary sarcomas of the lungs and mediastinum are rare and few data are reported on treatment and results of therapy.
  • Pts characteristics: median age 41 (19-80 y), male/female 19/12; symptoms at diagnosis: dyspnoea (42%), chest and shoulder pain (39%), cough (35%), hemophtoae (13%), discomfort (10%).
  • 4 pts had a previous history of mediastinal radiation for Hodgkin's and non-Hodgkin's linfomas.
  • 5 mediastinal tumours were located as follows: 2 in anterior part, 1 in posterior and 2 in the middle (sarcomas of the heart).
  • RESULTS: In 20/31 cases the tumour was immediately resected (3 mediastinal masses and 17 lung sarcomas).
  • Neoadjuvant chemotherapy was performed in 4 cases (3 resected).
  • The histology were: peripheral nerve tumour 7, leiomyosarcoma 4, MFH 2, fibrosarcoma 2, liposarcoma 1, angiosarcoma 2, undifferentiated sarcoma 1, solitary fibrous tumour 2, rhabdomyosarcoma 2, synovialsarcoma 2, pulmonary artery sarcoma 1, pleuropolmonary blastoma 1, malignant hemangiopericytoma 1, mixoid chondrosarcoma 1, ectopic osteosarcoma 1, aggressive fibromatosis 1.
  • Only 4 pts received neoadjuvant chemotherapy, 11 adjuvant CT, 5 exclusive CT + RT for inoperable disease.
  • CONCLUSIONS: Primary sarcomas of the lungs and mediastinum have a very severe prognosis.
  • Surgical resection is the fundamental therapy, but in the future the role of neoadjuvant CT will increase.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963390.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Michiels A, Hubens G, Ruppert M, Balliu L, Vaneerdeweg W: Giant liposarcoma of the stomach involving the mediastinum. Acta Chir Belg; 2007 Jul-Aug;107(4):468-71
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Giant liposarcoma of the stomach involving the mediastinum.
  • MRI showed a giant tumour of the stomach wall, invading the surrounding organs, as well as the mediastinal region.
  • After surgical 'en-bloc' resection of the tumour, histopathologic examination yielded a diagnosis of pleiomorphic liposarcoma.
  • Because of the bad prognosis of this histologic type, the patient received adjuvant chemotherapy: a combination of doxorubicin and ifosfamide (MAI).
  • Palliative chemotherapy was started with the intent to prolong the young patient's life.
  • Although liposarcoma is a very common soft tissue sarcoma, it is rarely seen in the stomach.
  • The standard therapy is surgical excision.
  • Over the last years, adjuvant therapy became more accepted.
  • Drugs of choice are doxorubicin and ifosfamide, although the benefits of this therapy are still largely unknown and doubtful.
  • [MeSH-major] Liposarcoma / pathology. Mediastinum / pathology. Stomach Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness

  • Genetic Alliance. consumer health - Liposarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17966553.001).
  • [ISSN] 0001-5458
  • [Journal-full-title] Acta chirurgica Belgica
  • [ISO-abbreviation] Acta Chir. Belg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Belgium
  •  go-up   go-down


19. Stevenson WS, Vincent PC, Iland HJ: Disseminated granulocytic sarcoma treated with allogeneic peripheral blood stem-cell transplantation. Leuk Lymphoma; 2002 Nov;43(11):2221-4
Genetic Alliance. consumer health - Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Disseminated granulocytic sarcoma treated with allogeneic peripheral blood stem-cell transplantation.
  • Primary granulocytic sarcoma is a rare disorder that presents as an extramedullary myeloid cell tumour.
  • In this case, we describe a 35-year-old woman who developed widely disseminated granulocytic sarcomas three months after she received local radiotherapy to a primary granulocytic sarcoma of the cervical spine.
  • These disseminated sarcomas initially responded to combination chemotherapy but this approach was only partly successful as the woman was left with increasing residual disease in the mediastinum.
  • This case demonstrates the effectiveness of allogeneic stem-cell transplantation in the treatment of progressive granulocytic sarcoma present after high-dose chemotherapy.
  • [MeSH-major] Peripheral Blood Stem Cell Transplantation. Sarcoma, Myeloid / therapy
  • [MeSH-minor] Adult. Combined Modality Therapy. Female. Gallium Radioisotopes. Humans. Neoplasm Invasiveness. Pleural Effusion, Malignant / radionuclide imaging. Pleural Effusion, Malignant / therapy. Remission Induction. Transplantation, Homologous

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12533051.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Gallium Radioisotopes
  •  go-up   go-down


20. Ketata W, Fouzi S, Msaad S, Ben Amira S, Yangui I, Ayoub A: [Thymoma associated with pure red cell aplasia and Kaposi's sarcoma]. Rev Mal Respir; 2009 Jan;26(1):78-82
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Thymoma associated with pure red cell aplasia and Kaposi's sarcoma].
  • INTRODUCTION: Thymoma is a rare tumor which represents about 20% of mediastinal tumors.
  • Thoracic imaging revealed a soft tissue mass in the anterior mediastinum with associated bilateral pleural effusion and mediastinal lymphadenopathy.
  • Histological examination confirmed the diagnosis of thymoma.
  • The patient was treated with 4 cycles of chemotherapy which led to a partial regression of the mass.
  • The course was marked by the occurrence of a pure red cell aplasia requiring corticosteroid therapy which caused the disappearance of the anemia.
  • However, bluish nodules appeared on the patients legs which when biopsied were found to represent Kaposi's sarcoma.
  • The patient was treated with chemotherapy (vinblastine) without any improvement of the cutaneous lesions.
  • CONCLUSION: Our case describes the association of a thymoma, pure red cell aplasia and Kaposi's sarcoma.
  • [MeSH-major] Neoplasms, Second Primary. Red-Cell Aplasia, Pure / etiology. Sarcoma, Kaposi. Skin Neoplasms. Thymoma. Thymus Neoplasms
  • [MeSH-minor] Anti-Inflammatory Agents / administration & dosage. Anti-Inflammatory Agents / therapeutic use. Antineoplastic Agents, Phytogenic / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Female. Glucocorticoids / administration & dosage. Glucocorticoids / therapeutic use. Humans. Immunohistochemistry. Mediastinoscopy. Middle Aged. Prednisone / administration & dosage. Prednisone / therapeutic use. Radiography, Thoracic. Time Factors. Tomography, X-Ray Computed. Treatment Outcome. Vinblastine / therapeutic use

  • Genetic Alliance. consumer health - Pure red cell aplasia.
  • MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • MedlinePlus Health Information. consumer health - Thymus Cancer.
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19212295.001).
  • [ISSN] 0761-8425
  • [Journal-full-title] Revue des maladies respiratoires
  • [ISO-abbreviation] Rev Mal Respir
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 0 / Antineoplastic Agents, Phytogenic; 0 / Glucocorticoids; 5V9KLZ54CY / Vinblastine; VB0R961HZT / Prednisone
  •  go-up   go-down


21. Kaira K, Ishizuka T, Sunaga N, Hashimoto K, Yanagitani N, Nonaka T, Ebara T, Hisada T, Mori M: Primary mediastinal synovial sarcoma: a report of 2 cases. J Comput Assist Tomogr; 2008 Mar-Apr;32(2):238-41
Genetic Alliance. consumer health - Synovial sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary mediastinal synovial sarcoma: a report of 2 cases.
  • Synovial sarcoma is the third most common histological type of extremity soft tissue sarcoma.
  • However, primary mediastinal synovial sarcoma is extremely rare.
  • We present 2 cases of unresectable primary mediastinal synovial sarcoma.
  • They were treated with radiotherapy and chemotherapy.
  • The radiographic findings and treatment were discussed.
  • [MeSH-major] Mediastinal Neoplasms / diagnosis. Sarcoma, Synovial / diagnosis
  • [MeSH-minor] Back Pain / etiology. Biopsy, Needle. Chest Pain / etiology. Deglutition Disorders / etiology. Diagnosis, Differential. Esophagus / physiopathology. Fatal Outcome. Female. Gastrostomy. Humans. Magnetic Resonance Imaging. Male. Mediastinum / pathology. Mediastinum / radiography. Mediastinum / radionuclide imaging. Middle Aged. Neoplasm Recurrence, Local. Positron-Emission Tomography. Rare Diseases. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18379309.001).
  • [ISSN] 0363-8715
  • [Journal-full-title] Journal of computer assisted tomography
  • [ISO-abbreviation] J Comput Assist Tomogr
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Nguyen LN, Ha CS, Hess M, Romaguera JE, Manning JT, Cabanillas F, Cox JD: The outcome of combined-modality treatments for stage I and II primary large B-cell lymphoma of the mediastinum. Int J Radiat Oncol Biol Phys; 2000 Jul 15;47(5):1281-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The outcome of combined-modality treatments for stage I and II primary large B-cell lymphoma of the mediastinum.
  • PURPOSE: Primary mediastinal large B-cell lymphoma (PML) has clinicopathologic features distinct from those of other diffuse large-cell lymphomas.
  • However, the optimal treatment for this tumor is evolving, and in particular, the role of radiation therapy remains undefined.
  • We conducted a retrospective review to evaluate the role of radiation therapy in this disease.
  • All patients were treated with doxorubicin-based chemotherapy, and 35 patients received radiation therapy.
  • For most patients who received radiation therapy, an involved field or a modified-mantle field was used, and a dose of 40 Gy in 20 fractions or 39.6 Gy in 22 fractions was administered.
  • Thirty-five patients achieved a complete response; 32 of these patients received radiation therapy.
  • Only 2 of the 5 completed the planned course of radiation therapy; both had massive mediastinal disease.
  • There was no treatment-related death from the initial chemotherapy or radiation therapy.
  • One patient developed a second malignancy (sarcoma) within the radiation field after 13 years.
  • CONCLUSION: We recommend consolidative radiation therapy in view of the excellent local control and the lack of significant toxicity.
  • Modified mantle or involved field appears to be an adequate volume, and 39.6-40 Gy appears to be an adequate dose.
  • [MeSH-major] Lymphoma, B-Cell / drug therapy. Lymphoma, B-Cell / radiotherapy. Lymphoma, Large B-Cell, Diffuse / drug therapy. Lymphoma, Large B-Cell, Diffuse / radiotherapy
  • [MeSH-minor] Adolescent. Adult. Aged. Analysis of Variance. Combined Modality Therapy. Female. Hematopoietic Stem Cell Transplantation. Humans. Male. Middle Aged. Neoplasm Staging. Recurrence. Retrospective Studies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10889382.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  •  go-up   go-down


23. Jiang L, Admirand JH, Moran C, Ford RJ, Bueso-Ramos CE: Mediastinal follicular dendritic cell sarcoma involving bone marrow: a case report and review of the literature. Ann Diagn Pathol; 2006 Dec;10(6):357-62
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mediastinal follicular dendritic cell sarcoma involving bone marrow: a case report and review of the literature.
  • We report a rare case of mediastinal follicular dendritic cell (FDC) sarcoma involving the bone marrow.
  • The patient, a 46-year-old woman, had a clinically aggressive tumor in the anterior mediastinum that was initially diagnosed as a diffuse B-cell lymphoma.
  • She received chemotherapy but showed no significant improvement.
  • The diagnosis of FDC sarcoma was made based on histological examination and immunohistochemical findings, including strong positive staining of tumor cells for CD21, CD23, clusterin, and epidermal growth factor receptor (EGFR) and negative staining for CD20, CD30, CD45, CD1a, S-100, vimentin, and keratin cocktail.
  • Histological examination and immunohistochemical studies of a previous biopsy of the mediastinal mass confirmed the diagnosis of mediastinal FDC sarcoma.
  • The patient was treated with an appropriate chemotherapy regimen; 1 month later, follow-up bone marrow biopsy revealed no tumor cells.
  • Although FDC sarcoma is considered a low-grade tumor, the tumor in the present case not only developed at an unusual location with bone metastasis but also involved bone marrow.
  • This case also highlights the utility of EGFR as an immunohistochemical marker of dendritic cell tumors that could be used as a diagnostic tool and guide for choosing appropriate chemotherapy regimens.
  • [MeSH-major] Bone Marrow / pathology. Dendritic Cells, Follicular / pathology. Mediastinal Neoplasms / pathology. Sarcoma / pathology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / analysis. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Etoposide / administration & dosage. Female. Humans. Ifosfamide / administration & dosage. Immunoenzyme Techniques. Methotrexate / administration & dosage. Middle Aged. Taxoids / administration & dosage. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17126255.001).
  • [ISSN] 1092-9134
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Taxoids; 0W860991D6 / Deoxycytidine; 15H5577CQD / docetaxel; 6PLQ3CP4P3 / Etoposide; B76N6SBZ8R / gemcitabine; UM20QQM95Y / Ifosfamide; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


24. Anderson P, Salazar-Abshire M: Improving outcomes in difficult bone cancers using multimodality therapy, including radiation: physician and nursing perspectives. Curr Oncol Rep; 2006 Nov;8(6):415-22
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Improving outcomes in difficult bone cancers using multimodality therapy, including radiation: physician and nursing perspectives.
  • Principles of therapy are similar for Ewing's sarcoma and osteosarcoma.
  • Chemotherapy or surgery alone cures few patients.
  • The spine, sacrum, pelvis, ankle, hand, mediastinum, pulmonary hilum, and chest wall are examples of bone cancer locations for which surgery is difficult.
  • Patients with positive margins may need radiation and may experience systemic therapy delay, recurrence, loss of function, or any combination of these.
  • When radiation is used as a means of local control, concomitant chemotherapy can increase its effectiveness.
  • Options for difficult Ewing's sarcoma and osteosarcoma situations and multimodality solutions, including 1 mCi/kg of samarium and proton therapy, are discussed.
  • Combination radiation and chemotherapy regimens are summarized, and organization of patients, caregivers, and medical teams for multimodality therapy is described, along with tools used in our institution that aid in this process.
  • [MeSH-major] Bone Neoplasms / therapy. Nurses / organization & administration. Osteosarcoma / therapy. Sarcoma, Ewing / therapy
  • [MeSH-minor] Combined Modality Therapy. Drug Therapy, Combination. Humans. Organization and Administration. Referral and Consultation / organization & administration. Secondary Prevention. Social Facilitation. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet Oncol. 2005 Feb;6(2):93-102 [15683818.001]
  • [Cites] J Clin Oncol. 2005 Mar 20;23(9):2004-11 [15774791.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Feb 1;64(2):544-50 [16198063.001]
  • [Cites] Expert Opin Pharmacother. 2006 Aug;7(11):1475-86 [16859431.001]
  • [Cites] J Surg Res. 2006 Mar;131(1):26-40 [16154153.001]
  • [Cites] Curr Oncol Rep. 2004 Jul;6(4):315-20 [15161588.001]
  • [Cites] Rays. 2003 Jul-Sep;28(3):211-5 [15018309.001]
  • [Cites] Mayo Clin Proc. 2003 Feb;78(2):147-55 [12583525.001]
  • [Cites] Pediatr Blood Cancer. 2004 Jan;42(1):46-51 [14752794.001]
  • [Cites] J Clin Oncol. 2002 Jan 15;20(2):426-33 [11786570.001]
  • [Cites] AJR Am J Roentgenol. 2005 Apr;184(4):1293-304 [15788613.001]
  • [Cites] Technol Cancer Res Treat. 2006 Apr;5(2):73-9 [16551127.001]
  • [Cites] Curr Cancer Drug Targets. 2006 Mar;6(2):123-33 [16529542.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Feb 1;61(2):492-8 [15667972.001]
  • [Cites] Pediatr Blood Cancer. 2004 May;42(5):471-6 [15049023.001]
  • [Cites] Exp Cell Res. 2004 May 1;295(2):469-87 [15093745.001]
  • [Cites] Adv Exp Med Biol. 2003;532:27-37 [12908547.001]
  • [Cites] Curr Opin Gastroenterol. 2005 Mar;21(2):216-22 [15711216.001]
  • [Cites] Clin Cancer Res. 2002 Nov;8(11):3622-7 [12429654.001]
  • [Cites] Anticancer Res. 2005 Mar-Apr;25(2A):947-54 [15868932.001]
  • [Cites] Am J Med Genet. 2002 Oct 30;115(3):189-93 [12407700.001]
  • [Cites] J Vasc Interv Radiol. 2005 Oct;16(10):1365-71 [16221908.001]
  • [Cites] J Nucl Med. 2003 Jun;44(6):930-42 [12791822.001]
  • [Cites] J Clin Pathol. 2003 Feb;56(2):96-102 [12560386.001]
  • [Cites] Pediatr Blood Cancer. 2006 Sep;47(3):231 [16206195.001]
  • [Cites] Diagn Cytopathol. 1996 Jul;15(1):17-22 [8807247.001]
  • [Cites] J Clin Oncol. 2004 Jan 15;22(2):300-6 [14722039.001]
  • [Cites] Cancer. 2005 Oct 15;104(8):1713-20 [16121404.001]
  • [Cites] Eur J Cancer. 2003 Jan;39(1):19-30 [12504654.001]
  • [Cites] Hematol Oncol. 2006 Mar;24(1):14-21 [16400699.001]
  • [Cites] Adv Cancer Res. 1985;43:175-203 [2581424.001]
  • [Cites] J Pediatr Oncol Nurs. 2005 Nov-Dec;22(6):339-52 [16216896.001]
  • [Cites] Future Oncol. 2006 Jun;2(3):333-43 [16787112.001]
  • [Cites] Radiother Oncol. 1997 Oct;45(1):63-70 [9364633.001]
  • [Cites] Cancer Imaging. 2005 Sep 21;5:103-9 [16305946.001]
  • [Cites] Semin Oncol. 1977 Mar;4(1):177-26 [190702.001]
  • [Cites] Cancer Genet Cytogenet. 2003 Jan 15;140(2):145-52 [12645653.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Oct 1;63(2):362-72 [16168831.001]
  • [Cites] Int J Cancer. 2006 Aug 15;119(4):839-46 [16557578.001]
  • [Cites] J Pediatr Hematol Oncol. 2005 Apr;27(4):215-8 [15838394.001]
  • [Cites] Annu Rev Med. 2006;57:1-18 [16409133.001]
  • [Cites] Clin Cancer Res. 2004 Feb 1;10 (3):840-8 [14871959.001]
  • [Cites] J Bone Joint Surg Am. 1975 Jan;57(1):10-6 [1123355.001]
  • [Cites] Radiology. 2005 Apr;235(1):289-98 [15798173.001]
  • [Cites] J Clin Oncol. 1996 Mar;14(3):848-58 [8622033.001]
  • [Cites] Clin Adv Hematol Oncol. 2004 Jun;2(6):355-6 [16163204.001]
  • [Cites] Cancer. 2002 Nov 15;95(10):2202-10 [12412175.001]
  • [Cites] Apoptosis. 2005 Jan;10(1):177-84 [15711933.001]
  • [Cites] J Clin Oncol. 2005 Jan 20;23(3):559-68 [15659502.001]
  • (PMID = 17040619.001).
  • [ISSN] 1523-3790
  • [Journal-full-title] Current oncology reports
  • [ISO-abbreviation] Curr Oncol Rep
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 50
  •  go-up   go-down


25. Łacko A, Włodarska I, Zymliński R, Mazur G, Wróbel T, Gisterek I: [Cardiac toxicity in cancer therapy]. Pol Merkur Lekarski; 2002 Jul;13(73):79-85
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Cardiac toxicity in cancer therapy].
  • The aim of this article is to review (based on the literature data) the mechanism of chemotherapy- and radiation-induced cardiac toxicity, diagnostic procedures and methods of reducing this toxicity.
  • Cardiac toxicity associated with chemotherapy and radiotherapy may be life threatening, can limit the dose and duration of the treatment and certainly adversely affect short-term and long-term quality of life.
  • The frequency of cardiomyopathy may be reduced by modifying the schedule of administration, patients selection considering risk factors, careful cardiac monitoring during chemotherapy, using less toxic doxorubicin analogues and liposomal formulation.
  • The use of pharmacological protection with dexrazoxane remains controversial.
  • A substantial risk of cardiotoxicity may be associated with radiotherapy of the chest and mediastinum.
  • Moreover, radiotherapy may have an additive affect to chemotherapy-induced toxicity.
  • However, with the use of modern treatment techniques radiation cardiomyopathy is uncommon.
  • A group of patients at risk of cardiac complication are patients with breast cancer, Hodgkin's and non-Hodgkin's lymphomas and soft tissue sarcomas.
  • [MeSH-major] Antibiotics, Antineoplastic / adverse effects. Cardiomyopathy, Dilated / etiology. Neoplasms / drug therapy. Radiotherapy, Adjuvant / adverse effects
  • [MeSH-minor] Breast Neoplasms / drug therapy. Cardiovascular Agents / therapeutic use. Dose-Response Relationship, Drug. Dose-Response Relationship, Radiation. Female. Hodgkin Disease / drug therapy. Humans. Lymphoma, Non-Hodgkin / drug therapy. Razoxane / therapeutic use. Risk Factors. Sarcoma / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12362515.001).
  • [ISSN] 1426-9686
  • [Journal-full-title] Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego
  • [ISO-abbreviation] Pol. Merkur. Lekarski
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Cardiovascular Agents; 5AR83PR647 / Razoxane
  • [Number-of-references] 39
  •  go-up   go-down


26. Malagón HD, Valdez AM, Moran CA, Suster S: Germ cell tumors with sarcomatous components: a clinicopathologic and immunohistochemical study of 46 cases. Am J Surg Pathol; 2007 Sep;31(9):1356-62
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Twenty-three tumors arose in the mediastinum, 2 in the retroperitoneum, and 21 in the gonads.
  • The SC included embryonal rhabdomyosarcoma (29), angiosarcoma (6), leiomyosarcoma (4), undifferentiated sarcoma (3), myxoid liposarcoma (1), malignant peripheral nerve sheath tumor (1), malignant "triton" tumor (1), and epithelioid hemangioendothelioma (1).
  • All patients were treated by cisplatinum-based chemotherapy plus other agents followed by surgery.
  • [MeSH-major] Immunohistochemistry. Mediastinal Neoplasms / diagnosis. Neoplasms, Germ Cell and Embryonal / diagnosis. Ovarian Neoplasms / diagnosis. Retroperitoneal Neoplasms / diagnosis. Sarcoma / diagnosis. Testicular Neoplasms / diagnosis
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Combined Chemotherapy Protocols. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Metastasis. Neoplasm Staging. Orchiectomy. Ovariectomy. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17721191.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


27. Michael H, Lucia J, Foster RS, Ulbright TM: The pathology of late recurrence of testicular germ cell tumors. Am J Surg Pathol; 2000 Feb;24(2):257-73
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A total of 91 men had histologically documented late recurrences of testicular germ cell tumors characterized by a complete response to treatment with a subsequent disease-free interval of at least 2 years and no evidence of a second primary lesion.
  • Ninety percent of the patients for whom information was available received chemotherapy shortly after their initial diagnosis of testicular germ cell tumors; most of the other patients were known to have stage I disease initially.
  • Thus, teratoma was the most common type of neoplasm in late recurrences.
  • Excluding teratoma coexisting with other types of neoplasms, yolk sac tumor was the most frequent type of tumor in patients with late recurrence.
  • It occurred in 47% of patients, either alone or with teratoma, another nonteratomatous germ cell tumor type, or a "nongerm cell malignant tumor."
  • Unusual types of yolk sac tumor, including glandular, parietal, clear cell, and pleomorphic patterns, were seen frequently in late recurrences and often raised differential diagnostic problems with "nongerm cell" carcinomas.
  • A smaller number of late recurrences consisted of other types of neoplasms.
  • "Nongerm cell malignant tumors," including both sarcomas and carcinomas of various types, occurred in 23% of late-recurrence patients, either alone or with a nonteratomatous germ cell tumor.
  • Late recurrences were seen in many different sites in these patients, including the retroperitoneum, abdomen, pelvis, liver, mediastinum, lung, bone (femur, vertebra, and rib), lymph nodes outside the retroperitoneum and mediastinum (supraclavicular, neck, and axillary regions), scrotum and inguinal regions, adrenal gland, chest wall, and buttocks.
  • Patients whose late recurrences consisted of pure "nongerm cell malignant tumor" or pure germ cell tumor (yolk sac tumor or other types) had a much worse prognosis: Only 36% to 37% were alive with no evidence of disease.
  • Patients with two different types of nonteratomatous malignancies in their late recurrences had a dismal clinical course: Only 17% with both yolk sac tumor and other nonteratomatous germ cell tumor had no evidence of disease, whereas no patient with both nonteratomatous germ cell tumor and "nongerm cell malignant tumor" was disease free.
  • Furthermore, late recurrence is not likely to respond to chemotherapy and is best treated by surgical excision when possible.
  • [MeSH-minor] Adolescent. Adult. Carcinoma, Embryonal / complications. Carcinoma, Embryonal / pathology. Carcinoma, Embryonal / therapy. Choriocarcinoma / complications. Choriocarcinoma / pathology. Choriocarcinoma / therapy. Endodermal Sinus Tumor / complications. Endodermal Sinus Tumor / pathology. Endodermal Sinus Tumor / therapy. Fluorescent Antibody Technique, Direct. Humans. Male. Neoplasm Staging. Neoplasms, Second Primary / pathology. Neoplasms, Second Primary / therapy. Sarcoma / complications. Sarcoma / pathology. Sarcoma / therapy. Seminoma / complications. Seminoma / pathology. Seminoma / therapy. Teratoma / complications. Teratoma / pathology. Teratoma / therapy

  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10680894.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  •  go-up   go-down


28. Chaiwun B, Sukhamwang N, Ya-In C, Shuangshoti S: Bilateral low-grade B-cell lymphoma of the breast: a case report with cytological, histological and immunohistochemical studies. J Med Assoc Thai; 2009 Jun;92(6):865-7
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Histological and immunohistochemical studies of an incisional biopsy specimen of the left breast lesion confirmed the diagnosis of low-grade B-cell lymphoma.
  • Computerized tomographic scans of chest and abdomen revealed multiple lymphadenopathy in the mediastinum and intra-abdomen.
  • After receiving chemotherapy, marked reduction in size of both breast masses and the internal lymph nodes was observed.
  • FNA is an inexpensive diagnostic tool for breast lumps that can reliably distinguish carcinoma, sarcoma and lymphoma.
  • [MeSH-minor] Antineoplastic Agents, Alkylating / therapeutic use. Antineoplastic Agents, Phytogenic / therapeutic use. Biopsy, Fine-Needle. Cyclophosphamide / therapeutic use. Female. Glucocorticoids / therapeutic use. Humans. Lymphatic Diseases. Middle Aged. Prednisolone / therapeutic use. Vincristine / therapeutic use

  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19530595.001).
  • [ISSN] 0125-2208
  • [Journal-full-title] Journal of the Medical Association of Thailand = Chotmaihet thangphaet
  • [ISO-abbreviation] J Med Assoc Thai
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Thailand
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Antineoplastic Agents, Phytogenic; 0 / Glucocorticoids; 5J49Q6B70F / Vincristine; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone
  •  go-up   go-down


29. Michel M, Pratt JW: Anterior mediastinal nonseminomatous germ cell tumor with malignant transformation: a case report. Curr Surg; 2004 Nov-Dec;61(6):576-9
Genetic Alliance. consumer health - Nonseminomatous germ cell tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anterior mediastinal nonseminomatous germ cell tumor with malignant transformation: a case report.
  • OBJECTIVE: We report a case of a 21-year-old man who presented with the unusual symptoms of heart failure and was found to have an anterior mediastinal yolk sac tumor.
  • RESULTS: The patient was treated with the current standard of neoadjuvant chemotherapy: bleomycin, etoposide, and cisplatin (BEP) with marked reduction in tumor size, followed by en bloc surgical resection.
  • The final pathology revealed teratoma with malignant change: chondrosarcoma, adenocarcinoma, and poorly differentiated sarcoma.
  • CONCLUSIONS: This is a rare initial presentation of an anterior mediastinal germ-cell tumor with treatment consisting of neoadjuvant therapy and surgical resection.
  • [MeSH-major] Endodermal Sinus Tumor / pathology. Mediastinal Neoplasms / pathology
  • [MeSH-minor] Adult. Cell Transformation, Neoplastic / pathology. Heart Failure / etiology. Humans. Male. Mediastinum / pathology. Neoplasm Metastasis. Teratoma / pathology

  • Genetic Alliance. consumer health - Malignant germ cell tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15590027.001).
  • [ISSN] 0149-7944
  • [Journal-full-title] Current surgery
  • [ISO-abbreviation] Curr Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 17
  •  go-up   go-down


30. Terenziani M, D'Angelo P, Bisogno G, Boldrini R, Cecchetto G, Collini P, Conte M, De Laurentis T, Ilari I, Indolfi P, Inserra A, Piva L, Siracusa F, Spreafico F, Tamaro P, Lo Curto M: Teratoma with a malignant somatic component in pediatric patients: the Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP) experience. Pediatr Blood Cancer; 2010 Apr;54(4):532-7
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PROCEDURE: The Associazione Italiana Ematologia Oncologia Pediatrica identified 14 cases of TMSC.
  • RESULTS: The series (9 female, 5 male) showed the following disease: testis (2), sacrococcygeal (3), ovary (3), retroperitoneum (3), mediastinum (2), and foot soft tissue (1).
  • Distribution of the somatic component was: carcinoma (4), pancreatic neuroendocrine tumor (1), neuroblastoma (3), rhabdomyosarcoma (3), rhabdomyosarcoma plus liposarcoma, chondrosarcoma, neurogenic sarcoma (1), chondrosarcoma plus neuroectodermal sarcoma (1), malignant peripheral nerve sheath tumor (1).
  • Chemotherapy optimized for histology should include reagents directed to the somatic malignancy, if chemosensitive.
  • Malignant GCT warrants GCT-directed chemotherapy.
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Female. Humans. Infant. Infant, Newborn. Italy. Male. Neoplasm Staging. Prognosis. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Teratoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20049928.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


31. Athanasiou A, Vanel D, El Mesbahi O, Theodore C, Fizazi K: Non-germ cell tumours arising in germ cell tumours (teratoma with malignant transformation) in men: CT and MR findings. Eur J Radiol; 2009 Feb;69(2):230-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • All patients had computed tomography (CT) and/or magnetic resonance (MR) studies before and after initial surgery and chemotherapy, as well as during follow-up.
  • Imaging findings were correlated with the response to treatment and with overall survival.
  • Sarcoma was identified in 10 out of 14 patients, with rhabdomyosarcoma ranking first (n=4), followed by osteosarcoma (n=2), fusiform cell sarcoma (n=1), undifferentiated sarcoma (n=1), neurosarcoma (n=1) and myxoid sarcoma (n=1).
  • Other histological types of malignant transformation included adenocarcinoma (n=3) and bronchoalveolar carcinoma (n=1).
  • Overall, 9 patients relapsed at a median time of 84 months (range 60-168).
  • RESULTS: Non-GCT malignant transformation was identified in the retroperitoneum (5), testis (3), mediastinum (3), peritoneum (2) and lungs (1).
  • The CT and MR imaging findings before treatment and after relapse were evaluated with emphasis on imaging features that could possibly imply the presence of malignant transformation (heterogeneously enhancing soft-tissue masses, ossified masses with calcified lymph nodes, diffuse epiploic thickening associated with ascites and peritoneal nodules, pulmonary alveolar infiltration with septal thickening).
  • Imaging can be useful as CT and MR findings may suggest this entity and lead to an early biopsy and appropriate treatment.
  • [MeSH-major] Cell Transformation, Neoplastic / pathology. Magnetic Resonance Imaging. Teratoma / diagnosis. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Teratoma.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19056194.001).
  • [ISSN] 1872-7727
  • [Journal-full-title] European journal of radiology
  • [ISO-abbreviation] Eur J Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  •  go-up   go-down






Advertisement